Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Downgrades MillerKnoll to Hold

Benchmark Downgrades MillerKnoll to Hold

Benchmark analyst Reuben Garner downgrades MillerKnoll (NASDAQ:MLKN) from Buy to Hold.

byBenzinga Newsdesk

November 30, 2022

1 minute read

Benchmark analyst Reuben Garner downgrades MillerKnoll (NASDAQ:MLKN) from Buy to Hold.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $13,000 Today

By Benzinga Insights

September 28, 10:30 AM

Cognizant Tech Solns (NASDAQ:CTSH) has outperformed the market over the past 20 years by 6.61% on an annualized…

CTSH

Analyst Ratings

Analyst Ratings for PerkinElmer

By Benzinga Insights

September 12, 12:07 PM

Analysts have provided the following ratings for PerkinElmer (NYSE:PKI) within the last quarter:

PKI

Adverum Biotechnologies Presents Nonclinical Data In Support Of Ixo-vec’s Phase 2 Clinical Development At ASGCT 2023 Annual Meeting

By Happy Mohamed

May 18, 9:09 AM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data

ADVM

Why This Analyst Downgraded Palantir As Economy ‘Appears To Be In Recession’

By AJ Fabino

July 22, 12:40 PM

Palantir Technologies Inc. (NYSE: PLTR) was downgraded from a Buy rating to a Neutral rating with no given price target on Friday by analysts at Monness Crespi Hardt & Co. Inc.

NFLX

Benchmark Downgrades MillerKnoll to Hold

Related Posts

$1000 Invested In This Stock 20 Years Ago Would Be Worth $13,000 Today

Analyst Ratings for PerkinElmer

Adverum Biotechnologies Presents Nonclinical Data In Support Of Ixo-vec’s Phase 2 Clinical Development At ASGCT 2023 Annual Meeting

Why This Analyst Downgraded Palantir As Economy ‘Appears To Be In Recession’